Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0009319 (colitis)
 19,384 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Fusidic acid is a well known antimicrobial agent due to its narrow spectrum of activity against Gram positive bacteria and especially staphylococci. Therefore, it is after used preventively against bacterial infection in traumatology, but the susceptibility of anaerobic bacteria is not well known. We have studied, the in vitro activity of sodium fusidate against 147 strains of anaerobic bacteria. This antibiotic has a moderate activity against Bacteroides, more significant against Clostridium, Peptococcus et Peptostreptococcus; it has no bactericidal activity. Clostridium difficile is different from other anaerobic bacteria because of its slow MIC and its MBC near to its MIC. Fusidic acid could be proposed for the treatment of pseudomembranous and antibiotic-associated colitis induced by Clostridium difficile.
 ...
PMID:[Activity of fusidic acid on strictly anaerobic bacteria]. 330 63

Twenty courses of fusidic acid were given to 16 patients with antibiotic-associated colitis caused by Clostridium difficile. Fusidic acid was given in a dose of 0.5-1.5 g daily for seven to 21 days. Diarrhoea disappeared rapidly. Clinical relapse occurred after five courses and once when the patient was still on treatment. Clinical cure with persistence or reappearance of toxin occurred in four further patients. Nineteen courses of metronidazole were given to 19 patients who experienced six failures or relapses. Seven courses of vancomycin were given to five patients, three of whom had had relapse. Five patients healed without treatment. The relapses occurred only in old and prostrated patients. They often recurred several times in the same patient. 0.5 g of fusidic acid daily appears to be as effective as vancomycin and metronidazole for the treatment of C. difficile-induced colitis.
 ...
PMID:Fusidic acid for the treatment of antibiotic-associated colitis induced by Clostridium difficile. 649 Jan 73

Fusidic acid and sodium fusidate (fusidin) are antibiotics with low toxicity and powerful immunomodulatory activities in vitro and in vivo. In this study we have evaluated the effect of fusidin on the development of dinitrobenzenesulfonic acid (DNB)-induced colitis in rats that serves as a preclinical model of human inflammatory bowel disease (IBD). The data show that when administered orally at the dose of 80 (but not 40) mg/kg body wt under a "therapeutic" regimen soon after DNB application, fusidin significantly ameliorates clinical, histological, and seroimmunological signs of disease. These entailed a significant reduction in body weight loss, smaller increase in colon weights, milder macroscopic damage, and lower histological scores. In addition, when sacrificed at the end of the study, fusidin-treated rats had significantly lower blood levels of tumor necrosis factor alpha and interferon-gamma compared with untreated controls. The present findings concur with the beneficial actions of fusidin in a pilot study conducted in patients with Crohn's disease and warrant controlled studies in humans with IBD.
 ...
PMID:Curative effects of sodium fusidate on the development of dinitrobenzenesulfonic acid-induced colitis in rats. 1469 40